Craig I Coleman1, Shivani Pandya2, Li Wang2, Onur Baser3, Jennifer Cai4, Mike Ingham4, Brahim Bookhart4. 1. University of Connecticut School of Pharmacy, Storrs, CT 06269, USA. 2. STATinMED Research, Plano, TX 75024, USA. 3. University of Michigan Medical School, Ann Arbor, MI 48109, USA. 4. Janssen Scientific Affairs, LLC, Real World Value & Evidence, Titusville, NJ 08560, USA.
Abstract
Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results: Patients were less likely to discontinue (p < 0.0001) or switch (p = 0.0048), more likely to add-on treatment (p = 0.0314), and achieve HbA1c <8.0% (p = 0.0364) or weight loss ≥5% (p < 0.0001) with canagliflozin versus GLP1RAs over 9 months. Mean HbA1c was similar at 3-month intervals over 9 months with canagliflozin and GLP1RAs. Conclusion: Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozin patients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RA patients.
Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results:Patients were less likely to discontinue (p < 0.0001) or switch (p = 0.0048), more likely to add-on treatment (p = 0.0314), and achieve HbA1c <8.0% (p = 0.0364) or weight loss ≥5% (p < 0.0001) with canagliflozin versus GLP1RAs over 9 months. Mean HbA1c was similar at 3-month intervals over 9 months with canagliflozin and GLP1RAs. Conclusion:Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozinpatients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RApatients.
Entities:
Keywords:
HbA1c; Type II diabetes mellitus; adherence; canagliflozin; glucagon-like peptide-1 receptor agonist; weight loss
Authors: Tracey Weiss; Lingfeng Yang; Richard D Carr; Sampriti Pal; Baanie Sawhney; Robert Boggs; Swapnil Rajpathak; Kristy Iglay Journal: BMJ Open Diabetes Res Care Date: 2022-01